Pfizer (PFE) Q1 FY26 earnings call

Pfizer delivered a strong Q1 FY26, surpassing revenue and EPS expectations, driven by robust performance from launched and acquired products and disciplined cost management. The company reaffirmed its full-year guidance, highlighting confidence in its strategic execution and pipeline progress. Recent legal developments, including the VYNDAMAX settlement, provide enhanced clarity on cash flow and a path to high single-digit revenue growth post-2028, supporting long-term shareholder value creation.